Market Expansion:
Geographic reach has broadened to about 25 U.S. states for Care+ in‑home preventive visits, with coverage spanning Medicare, Medicaid, and Marketplace lines of business. Materials from 2023–2026 indicate a step‑up from 5 states to roughly half the nation by February 2026.
Strategic Partnerships:
Collaborations with payers and providers are expanding, exemplified by Blue Cross Blue Shield of Michigan/Blue Care Network offering in‑home diabetic retinal screenings starting April 1, 2026 and UCI Health signaling plans to grow joint programs. Additional references highlight added payer/provider relationships through 2025–2026.
Investor Backing & Capital Strength:
A $55 million Series B closed on May 15, 2025 led by General Catalyst with participation from a16z Bio + Health and others, providing fuel to scale at‑home services. Third‑party trackers and coverage cite total funding in the roughly $92.6 million to ~$125 million range.
